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Due to the GC-rich, repetitive nature of C9orf72 hexanucleotide repeat expansions, PCR based detection
methods are challenging. Several limitations of PCR have been reported and overcoming these could help
to define the pathogenic range. There is also a need to develop improved repeat-primed PCR assays
which allow detection even in the presence of genomic variation around the repeat region. We have
optimised PCR conditions for the C9orf72 hexanucleotide repeat expansion, using betaine as a co-solvent
and specific cycling conditions, including slow ramping and a high denaturation temperature. We have
developed a flanking assay, and repeat-primed PCR assays for both 30 and 50 ends of the repeat
expansion, which when used together provide a robust strategy for detecting the presence or absence of
expansions greater than ~100 repeats, even in the presence of genomic variability at the 30 end of the
repeat. Using our assays, we have detected repeat expansions in 47/442 Scottish ALS patients. Further-
more, we recommend the combined use of these assays in a clinical diagnostic setting.
© 2016 Published by Elsevier Ltd.1. Introduction
A hexanucleotide repeat expansion (HRE) of a noncoding
GGGGCC repeat within the Chromosome 9 open reading frame 72
(C9orf72) gene has been identified as a major cause of amyotrophic
lateral sclerosis (ALS, MIM: 612069) and frontotemporal lobar
degeneration (FTLD, MIM: 600274) [1,2]. In the UK population, 7.5%
of patients with FTLD and 8.1% of patients with ALS have C9orf72
expansions greater than 32 repeats [3].
The threshold size range of pathogenic alleles has not been well
defined, and often relies on the technical cut-off of detection by PCR
based assays (30e50 repeats) [2,4]. There is one report of a stable
70 repeat allele in an unaffected individual expanding in his
offspring, but further studies are required to determine whether
anticipation is associated with this repeat expansion [5]. To ascer-
tain the minimal pathogenic repeat size, it is necessary to detectics Service, Western General
ry, et al., Improved PCR base
/dx.doi.org/10.1016/j.mcp.201and accurately measure repeat sizes in small expansion carriers.
Historically, Southern blotting has been regarded as the gold
standard method for detecting and sizing large repeat expansions
such as in Fragile X syndrome. However, improvements in PCR
based methods, particularly repeat-primed (RP-) PCR [6], has
meant that clinical diagnosis can now be made using PCR methods
alone. RP-PCR uses a locus-specific flanking primer along with a
paired repeat primer that amplifies from multiple sites within the
repeat, generating a characteristic ladder of fragments after capil-
lary electrophoresis. In C9orf72, somatic mosaicism for repeat
length in blood samples has been reported, and this can make ac-
curate interpretation of Southern blots challenging, as well as
making it difficult to predict any genotype-phenotype correlations
with varying repeat size [1,3,7,8]. For this reason, developing reli-
able and robust RP-PCR methods is important, and others agree
that Southern blot results should be interpreted in conjunction
with RP-PCR [3].
Within both research and diagnostic settings, it is desirable to
have high-throughput, rapid PCR based tests which are highly ac-
curate and do not require large amounts of input DNA. The chal-
lenges of PCR amplification of the 100% GC rich C9orf72 HRE haved methods for detecting C9orf72 hexanucleotide repeat expansions,
6.06.001
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wide variability in results obtained by different research labora-
tories using PCRmethods [9]. Furthermore, the presence of variable
deletions and insertions at the 30 end of the HRE [10], can adversely
affect the reliability of PCR assays targeting this region [11].
There are various ways in which PCR can be enhanced such as
the addition of co-solvents such as dimethyl sulfoxide and betaine,
modified Taq polymerase and alteration of cycling conditions [12].
Heat-pulse extension (HPE) PCR has been reported to successfully
allow amplification of repetitive GC-rich sequences similar to
C9orf72 HRE, and so in this study we used these cycling conditions
as a starting point to then optimise for these amplicons [12].
The objectives of this study were to develop a conventional
flanking PCR assay which could amplify repeat alleles beyond the
50e70 limit reported in the literature, and to optimise RP-PCR as-
says for both ends of the repeat to ascertain whether there were
greater than 100 repeats present. We also wanted to overcome the
issues of the Renton et al. assay where the expansion is not detected
by RP-PCR in cases with genomic variability adjacent to the HRE
[11]. These assays were then used to screen for C9orf72 HRE in ALS
patients from the Scottish population.
2. Materials and methods
2.1. Patients and DNA samples
442 consecutive DNA samples obtained from patients with ALS
who donated blood for research to the Scottish Regenerative
Neurology Tissue Bank, and were phenotyped as part of the Scot-
tish Motor Neurone Disease (MND) Register (between 1989 and
2015) were analysed. The diagnostic criteria used by the Scottish
MND Register were the Modified World Federation of Neurology
(1989e1994) or ‘El Escorial’ (1995 onwards) [13,14]. Clinical diag-
nostic samples received to the South East Scotland Genetics Service
for C9orf72 testing from 2013 to 2016 were also used for assay
development. In addition, positive control DNA samples derived
from lymphoblast cell lines were obtained from Coriell Cell Re-
positories. The Institute of Neurology (UCL, Queen Square, London)
shared positive control DNA derived from blood, from two short
expansion (60e120 repeats) carriers.
2.2. Ethics
Ethical approval for research analysis of the Scottish Regenera-
tive Neurology Tissue Bank samples affiliated to the Scottish MND
register was obtained from the East of Scotland Research Ethics
Service. NHS clinical diagnostic samples were consented for assay
development.
2.3. Molecular testing
DNA was extracted from whole blood samples by phenol-
chloroform, manual salting out, the Nucleon BACC3 genomic DNA
kit (Tepnel Life Sciences), or Chemagic DNA blood kit (Perkin
Elmer).
PCR reactions, in a total volume of 20 ml consisted of 0.8
Optimized DyNAzyme™ EXT buffer, 0.16 mM dATP, 0.16 mM dTTP,
0.56 mM dCTP, 0.56 mM dGTP, 1.8 M Betaine and 0.12 U/ml DyNA-
zyme™ EXT DNA Polymerase (ThermoFisher Scientific). For flank-
ing PCR, primers were at 1.25 mMand 20 ng DNAwas added. For RP-
PCR, primer concentrations were: FAM labelled flanking, 0.5 mM;
repeat, 0.25 mM and Tail R; 0.75 mM, and 200 ng DNA was added.
PCR primers are listed in Table 1. PCR amplification was carried out
on a Veriti® thermal cycler (Life Technologies). Cycling conditions
are shown in Table 2.Please cite this article in press as: E.M. Cleary, et al., Improved PCR base
Molecular and Cellular Probes (2016), http://dx.doi.org/10.1016/j.mcp.201PCR products were separated by capillary electrophoresis using
an ABI 3130xL with a 50 cm array (Life Technologies) with either
Genescan™ LIZ600 or LIZ1200 size standard (Life Technologies).
Data was analysed using GeneMarker® software v2.4.0 (Soft Ge-
netics). Alternatively, PCR products were separated on 0.8% Ultra-
Pure agarose (ThermoFisher Scientific) gels in TBE buffer with
100 bp DNA ladder (Promega) and 1 kb DNA extension ladder
(Invitrogen).
For Sanger sequencing, either flanking PCR or an alternative 30
RP-PCR was used (Table 1). PCR products were purified using
Agencourt Ampure XP (Beckman Coulter), as per the manufac-
turer’s instructions, using a Biomek® NX robot (Beckman Coulter).
Sequencing was then performed using R6 primer and BigDye®
Terminator v3.1 (Life Technologies). Agencourt CleanSeq (Beckman
Coulter) was used, according to the manufacturer’s instructions, to
clean-up sequencing products prior to capillary electrophoresis on
an ABI 3130xL (Life Technologies). Data was analysed using Muta-
tion Surveyor® software v4.0.8 (Soft Genetics).
3. Results
3.1. C9orf72 HRE frequency in the Scottish ALS population
We tested 442 archival DNA samples from the Scottish Regen-
erative Neurology Tissue Bank, linked to the Scottish MND Register,
collected from 1989 to 2015, using flanking PCR to assess the sizes
of normal alleles. 157 cases which gave a homozygous result on this
assay were then tested using both 30RP-PCR and 50RP-PCR, which
led to detection of C9orf72 expansions in 47 patients (10.6%), and
gave one equivocal result which could not be resolved due to
insufficient DNA. The repeat sizes that were obtained are shown in
Fig. 1, which shows a similar distribution to the UK population [3].
3.2. Optimal conditions for flanking PCR
We developed a PCR assay using primers flanking the C9orf72
HRE and applied the HPE PCR conditions developed for Fragile X
syndrome [12]. HPE PCR involves multiple heat pulses during the
extension phase of the cycling protocol to temporarily destabilize
GC rich structures which may otherwise lead to replication stalling
[12]. These conditions permitted superior amplification to that
achieved with Qiagen Multiplex PCR kit or Roche Fast Start High
Fidelity PCR system with standard cycling conditions (data not
shown). We then varied cycling conditions to determine the
annealing temperature, and whether high denaturation, slow
ramping or heat-pulse extension were required, and also the
optimal extension time. We found that the slow ramp from
annealing to extension phase and high denaturation temperature
were the most important features, and in this case the heat pulses
during extension were of no benefit (data not shown). The opti-
mised conditions gave relatively balanced amplification of normal
alleles, as highlighted in the series of samples with alleles ranging
between 2 and 26 repeats (Fig. 2aec). The Institute of Neurology,
UCL, Queen Square, London sent us two samples with ‘short’ ex-
pansions. The first was estimated as having 60 repeats, with
mosaicism for a large expansion (James Polke, personal commu-
nication), and another with 90 repeats in blood estimated by
Southern blotting [15]. These alleles had not been amplified using
existing PCR methods by ourselves or the Institute of Neurology
(data not shown). Using our method, we could detect alleles of
approximately 70 and 80 repeats, and revealed a high level of
mosaicism in both cases (Fig. 2def). The largest repeat size we
detected in blood was ~120 repeats, although we did note that a
large smear was present in a number of samples with expansions




Primer Sequence (50-30) Annealing temperature
Flanking PCR: 58 C
F3 FAM-AGCAAG CTCTGG AACTCA GGAGTC G
R6 CCTCAC TCACCC ACTCGC CAC
30 RP PCR: 62 C
R8 FAM-CGGGCG CAGGCA CCGCAA CC
Repeat F3 TACGCA TCCCAG TTTGAG ACGGGC CGGGGC CGGGGC CGG
Tail R TACGCA TCCCAG TTTGAG ACG
50 RP PCR: 62 C
F2 FAM-CTGTAG CAAGCT CTGGAA CTCAGG AGTCG
Repeat R TACGCA TCCCAG TTTGAG ACGCCC CGGCCC CGGCCC CGGCCC C
Tail R TACGCA TCCCAG TTTGAG ACG
30RP PCR (sequencing): 61 C
R6 CCTCAC TCACCC ACTCGC CAC
Repeat F TACGCA TCCCAG TTTGAG ACGGGG GCCGGG GCCGGG GCCGGG G
Tail R TACGCA TCCCAG TTTGAG ACG
Table 2
PCR cycling conditions.
94 C 7 min
95 C 45 s 35 cycles
98 C 10 s
58 C (flanking) or 62 C (RP-PCR) 30 s
78 C (slow ramp 0.6 C/s) 6 min
78 C 10 min
Fig. 1. Size distribution of the (GGGGCC)n repeat in Scottish ALS patients. Histogram showing frequency of (GGGGCC)n repeat sizes in Scottish ALS patients, with expansions
represented as 100 þ repeats. Homozygous normal flanking results, where there is no expansion detected by RP-PCR have been counted twice to give allele frequency. No ex-
pansions between 26 and 100 repeats were detected.
E.M. Cleary et al. / Molecular and Cellular Probes xxx (2016) 1e7 3detection, we tested lymphoblast cell line DNA from the Coriell Cell
Repository which was positive for C9orf72 HRE by RP-PCR. This
revealed material up to 5.7 kb, corresponding with approximately
900 repeats to have been amplified (Fig. 2f). There was amplifica-
tion of expandedmaterial in 4 out of 7 lines tested, andwe presume
that the other lines contained expansions which were beyond the
size limit of detection by this method. This is supported by previ-
ously published Southern blotting results for ND10966, ND11836
and ND14442 [16].
To calibrate our sizing assay, we sequenced 14 patient samples
with normal sized alleles to correlate the fragment size to repeat
length. However, we cannot exclude variation in flankingPlease cite this article in press as: E.M. Cleary, et al., Improved PCR base
Molecular and Cellular Probes (2016), http://dx.doi.org/10.1016/j.mcp.201sequences affecting the reported allele size, as has been reported by
others [9].3.3. Optimal conditions for RP-PCR
We designed primers for RP-PCR assays from both 30 and 50 ends
of the HRE. We compared different PCR cycling conditions andfound that the optimal conditions were the same as for flanking
PCR, but with annealing at 62 C.
For the 50 RP-PCR and 30 RP-PCR assays, the maximum length of
the amplicons which were obtained correlated with 100 and 160
repeats respectively. When including heat pulses [12] in the
extension phase of the 30 RP-PCR assay, we incidentally observed
that there was a lack of amplification of normal alleles in the
presence of an expansion, and used this assay to specifically
sequence the expanded allele. This allowed us to investigate
whether the optimised RP-PCR conditions permitted amplification
even in cases which had variability in the 30 end of the repeat,
which has previously been reported to hamper PCR [11]. Out of 47d methods for detecting C9orf72 hexanucleotide repeat expansions,
6.06.001
Fig. 2. Flanking PCR results. Capillary electrophoresis traces following flanking PCR, showing relatively balanced amplification of (a) 7 and 13 repeat alleles, (b) 2 and 20 repeat
alleles and (c) 8 and 26 repeat alleles, with some stuttering for the latter. (d) Capillary electrophoresis traces for a sample estimated to have 5; 60 repeats, with somatic mosaicism
for a large expansion by Southern blot and (e) a sample estimated to have 5; 70e120 repeats by Southern blot [15]. All traces are from GeneMarker (Soft Genetics) and x axis
corresponds to size in base pairs (bp) and y axis to relative fluorescent units (boxes in (d,e) show zoomed in trace of affected region (>30 repeats). (f) Agarose gel electrophoresis of
flanking PCR products with 100 bp and 1 kb extension DNA ladders. Lanes 1e4 Blood derived DNA: 1. Normal control (2; 5 repeats). 2. Normal control (8; 26 repeats). 3. Expansion
carrier (10; 60 mosaic repeats). 4. Expansion carrier; (5; 70e120 repeats). Lanes 5e11 Coriell Cell Repositories C9orf72 HRE positive LCL DNA: 5. ND09373 (10; Expansion unde-
tected). 6. ND09438 (11; 570 repeats). 7. ND10966 (9; Expansion undetected). 8. ND10973 (9; Expansion undetected). 9. ND11836 (8; 860 repeats). 10. ND12199 (6; 85 repeats). 11.
ND14442 (2; 600,700,920 repeats). 12. No DNA control. Southern blot results [16] are consistent with a lack of amplification of the largest expanded material in cell line DNA.
E.M. Cleary et al. / Molecular and Cellular Probes xxx (2016) 1e74patients who tested positive for the expansion, we found that 31 of
them had sequence which matched the reference sequence. This
left a further 16 (34%) that had some form of insertion or deletion
present at the 30 end of the repeat, as shown in Fig. 3.
A potential limitation of RP-PCR is preferential amplification of
normal sized products preventing amplification of large expan-
sions, and to investigate this issue we performed admixture ex-
periments for both 30RP-PCR and 50RP-PCR assays. Dilution of a
heterozygous expanded carrier, in a heterozygous normal control
with 2 and 5 repeats, showed that both assays could still detect an
expansion even when only present at 1%, as shown in Fig. 4.
For 156/157 homozygous normal patients tested, results for theFig. 3. Sequence variants detected. An illustration of sequence variants detected at the 30 en
(e) and insertions/duplications in red.
Please cite this article in press as: E.M. Cleary, et al., Improved PCR base
Molecular and Cellular Probes (2016), http://dx.doi.org/10.1016/j.mcp.20130 and 50 RP-PCR assays were concordant. The one discordant result
was apparently homozygous for 15 repeats on flanking PCR, and
only showed an expansion using the 30 RP-PCR assay. Further
analysis of heterozygous samples where one of the normal alleles
was 15 repeats or longer revealed that the 30 RP-PCR assay does not
drop to the baseline after the larger normal allele peak, unlike the 50
RP-PCR assay, as shown in Fig. 5. This effect is more pronounced the
larger the normal allele is, as the stuttering is more likely to go into
the affected range. Attempts to reduce this effect, by altering
annealing temperature, reducing polymerase concentration and
reducing cycle number failed to completely eliminate this PCR
artefact, as they also resulted in an undesirable weaker trace ford of the hexanucleotide repeat expansion. Deleted nucleotides are indicated as a dash
d methods for detecting C9orf72 hexanucleotide repeat expansions,
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Fig. 4. Sensitivity of RP-PCR for mosaicism. All capillary electrophoresis traces are of 30RP-PCR (left) and 50RP-PCR (right). The traces show amplification of heterozygous expanded
DNA (2; Expansion) at varying degrees of dilution (a) 100% (b) 50% (c) 10% (d) 1% and (e) 0% in heterozygous normal control DNA (2; 5 repeats). Traces are from GeneMarker (Soft
Genetics); the x axis corresponds to size in base pairs (bp) and y axis to relative fluorescent units (box shows zoomed in trace of affected region (>30 repeats).
E.M. Cleary et al. / Molecular and Cellular Probes xxx (2016) 1e7 5positive samples (data not shown).4. Discussion
We have developed robust PCR based methods for detecting the
HRE in C9orf72. The inclusion of betaine, alongwith Taq polymerase
which is optimised for long, GC-rich regions and slow-ramping PCR
cycling, all contribute to efficient PCR of this challenging genomic
region. We have used our PCR methods to screen a cohort of 442
Scottish ALS patients for the HRE, as well in a clinical diagnostic
setting for patients with ALS and FTLD.
The flanking PCR allows detection of alleles which are larger
than have previously been reported using similar methods.
Although the largest alleles were detected in cell line DNAwhich is
not a source routinely used in a diagnostic setting, this gives an
indication that the PCR is efficient and will be informative for blood
samples with stable expansions of similar size. As much C9orf72
research is performed on cell lines, this technique could be used to
monitor repeat stability in culture. The detection of repeats in the
70e120 repeat range by PCR and capillary electrophoresis allows a
more accurate size to be assigned as compared to agarose gel
electrophoresis and Southern blotting, which has a lower resolu-
tion and is also non-denaturing so more affected by secondary
structure formation [17].
For clinical diagnostic testing, it is important to be aware of the
common repeat sizes within the population as this can guide
testing. Suspicion arises when a patient is apparently homozygous
for a rare repeat size, particularly if these are in the 15e30 range
which could hamper PCR amplification [11]. In our experience,Please cite this article in press as: E.M. Cleary, et al., Improved PCR base
Molecular and Cellular Probes (2016), http://dx.doi.org/10.1016/j.mcp.201sequencing of the flanking PCR products in apparently homozygous
cases can also reveal normal alleles with genomic variability, which
has also been reported by others [9].
The RP-PCR assays that we have developed appear to be higher
yielding and produce a ladder of fragments corresponding with
over 100 repeats, which is longer than has previously been pub-
lished [1,2]. Importantly, our 30 RP-PCR assay has been shown to be
robust even in the presence of a number of genomic variations next
to the HRE. We detected a relatively higher degree of variation than
has been reported in studies based on Southern UK populations,
with a 10 bp deletion being reported commonly in Northern En-
gland [11]. The prevalence of C9orf72 expansions in the Scottish ALS
population is similar to that reported in other population based
series of ALS internationally [3,18].
The admixture experiments which were carried out, where
expansions can be detected even when diluted to 1% in a normal
background, suggest that these assays are not severely affected by
preferential amplification, and the conditions seem to be optimal
for PCR of longer fragments.We have observed that in the 30RP-PCR,
normal alleles of greater than 15 repeats can lead to a PCR artefact
with low level expanded material being observed. This presumed
primer-product or product-product interaction, leading to replica-
tion slippage can only be reduced by measures which also reduce
the production of expanded material in HRE positive cases. Thus,
this may be a limitation for product length for C9orf72 RP-PCR, as
the 50RP does not generate as large products and does not suffer
from this artefact. The prevalence of false positive results in the
study by Akimoto et al. [9] suggests that laboratories should be
aware of such test limitations.d methods for detecting C9orf72 hexanucleotide repeat expansions,
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Fig. 5. 30RP-PCR artefact present in samples with normal alleles greater than 15 repeats, which is not observed for 50RP-PCR. All capillary electrophoresis traces are of 30RP-PCR (left)
and 50RP-PCR (right). (a) Heterozygous normal sample (2; 5 repeats) (b) Heterozygous normal sample (2; 15 repeats) amplified with 30RP-PCR showing weak stuttering into the
affected range (522 rfu at 30 repeats), with 50RP-PCR showing limited presence of product >30 repeats (50 rfu at 30 repeats). (c) Heterozygous normal sample (8; 26 repeats)
amplified with 30RP-PCR showing stuttering into the affected range, with 50RP-PCR showing 10-fold weaker stuttering into the expanded range. (d) Heterozygous expansion carrier
showing stronger signal in the affected (>30 repeat) size range in both assays compared to the samples with large normal alleles. Traces are from GeneMarker (Soft Genetics); the x
axis corresponds to size in base pairs (bp) and y axis to relative fluorescent units (box shows zoomed in trace of affected region (>30 repeats).
E.M. Cleary et al. / Molecular and Cellular Probes xxx (2016) 1e765. Conclusion
We would recommend testing using all three PCR assays in a
clinical diagnostic setting, and ensuring there are concordant re-
sults prior to reporting. There may be rare cases (1/450 in this
study) which are homozygous normal on flanking PCR and an
expansion is only apparent in one RP-PCR assay, where reflex
testing with Southern blotting may be necessary to obtain a result.
Both RP-PCR assays should be used together to minimise the risk of
any rare genomic variability, including single nucleotide poly-
morphisms under primer binding sites, from affecting the test ac-
curacy. This is in line with recommendations for other repeat
expansion disorders, such as Myotonic Dystrophy type 1 [19].
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